The Kashi Cardiac Health Panel gives insight into how a patient’s genetic predisposition to cardiac problems can help healthcare providers optimize diagnosis and treatment.
Cardiovascular disease is a leading contributor to morbidity and mortality, with over 17 million deaths occuring annually worldwide. Risk increases in adults over the age of 60, and in part is atrributable to our inherited genetic makeup. Cardiovascular disease – which includes coronary heart disease, cerebrovascular disease, peripheral artery disease, and atherosclerosis – is heavily influenced by factors such as insulin resistance, hypertension, dyslipidemia, inflammation, and coagulation properties. Many of these factors can be mitigated by lifestyle changes including smoking cessation, increasing aerobic exercise, and eating a well-balanced diet, which can reduce the risk of catastrophic events such as myocardial infarction, or ischemic and hemorrhagic stroke. However, in some cases, particularly where family history of cardiovascular disease is prevalent, medications are needed to better manage health outcomes. In some patients, lifestyle and medication are still not enough, and greater intervention is necessary.
The Kashi Cardiac Health Panel is designed to highlight confounding factors barring appropriate cardiovascular risk reduction in patients. The panel focuses on eight genetic markers affecting hypertension, total cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, thrombotic risk, homocysteinemia, insulin resistance, and statin-induced myopathy risk.
Strong candidates for the Kashi Cardiac Health Panel include patients with:
- Treatment-resistant hypertension
- Poor control over cholesterol levels
- Personal history of angina, DVT, PE, CHF, MI or CVA
- Introduction of new statin medications
- Family history of cardiovascular disease
- Stroke or heart disease in the young
- Idiopathic cardiovascular disease
Test Categories Included in the Cardiac Health Panel
|GENETIC MARKERS||EFFECT ON CARDIAC HEALTH|
|ApoE||Impacts management of cholesterol levels and risk of heart attack, stroke, hypertension, and coronary disease|
|Factor II (Prothrombin)||Affects the body’s ability to form blood clots which is tied to the risk of many cardiovascular-related health outcomes|
|Factor V||Enhances body's coagulability which leads to thromboembolisms|
|MTHFR||Contributes to increased levels of homocysteine, a known risk factor for heart disease, atherosclerosis, and peripheral neuropathy|
|9p21||Associated with cellular growth and proliferation in relation to atherosclerosis, arterial stiffness and coronary artery disease|
|eNOS/NOS3||Influences nitric oxide levels leading to risk of endothelial dysfunction, and many subsequent cardiovascular effects|
|SLCO1B1*5||Modulates the body’s ability to metabolize statin medications, which are commonly prescribed to improve cholesterol|
|AGT||Key to maintaining blood pressure, patients who carry this mutation may be at an increased risk of developing hypertension|
Get Started Today
Make Kashi Health's Genetic Testing Part of your Patient's Treatment Plan.
- Wilson PWF. www.UpToDate.com. Overview of the risk equivalents and established risk factors for cardiovascular disease.
- Munir M et al. The association of 9p21-3 locus with coronary atherosclerosis: a systematic review and meta-analysis. Medical Genetics. 2014; 15:1-10.
- Karvanen J et al. The Impact of Newly Identified Loci on Coronary Heart Disease, Stroke and total Mortality in the MORGAM Prospective Cohorts. Genetic Epidemiology. 2009; 33:237-246.
- Zende PD et al. Apolipoprotein E Gene Polymorphism and Its Effect on Plasma Lipids in Arteriosclerosis. Journal of Clinical and Diagnostic Research. 2013; 7:2149-2152.
- Kotze MJ & SJ van Rensburg. Pathology supports genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer’s disease. Metabolic Brain Disease. 2012; 27:255-266.
- Szabo GV. The role and importance of gene polymorphisms in the development of atherosclerosis. Interventional Medicine & Applied Science. 2013; 5(1):46-51.
- Goracy I et al. C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of ischemic stroke in Polish subjects. J Appl Genet. 2009;50(1):63–7.
- Daly A. Pharmacogenetics of adverse drug reactions. Genome Medicine. 2013; 5 (5):1-12
- Gharani N et al. The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Medicine. 2013; 5 (93):1-19.
- Mendis S et al. World Health Organization; 2011. Global atlas on cardiovascular disease prevention and control.